nach oben

World Journal of Urology

Erschienen in:

10.09.2019 | Original Article

Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate

verfasst von: Stefan Ückert, George T. Kedia, Dimitrios Tsikas, Annika Simon, Andreas Bannowsky, Markus A. Kuczyk

Erschienen in: World Journal of Urology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The benign prostatic syndrome, comprising lower urinary tract symptomatology secondary to benign prostatic hyperplasia/enlargement, represents a major health care issue in westernized countries. The pharmacological management involves alpha-adrenoceptor antagonists, intervention into the hormonal control of prostate growth using inhibitors of the enzyme 5-alpha-reductase, and stimulation of the nitric oxide/cyclic GMP pathway by tadalafil, an inhibitor of the phosphodiesterase type 5.

Methods

This review summarizes the achievements which have been made in the development of drug candidates assumed to offer opportunities as beneficial treatment options in the management of the benign prostatic syndrome.

Results

A review of the literature has revealed that the line of development is focusing on drugs interfering with peripheral neuromuscular/neuronal mechanisms (nitric oxide donor drugs, agonists/antagonists of endogenous peptides, botulinum toxin, NX-1207), the steroidal axis (cetrorelix) or the metabolic turn-over (lonidamine), as well as the combination of drugs already established in the treatment of lower urinary tract symptomatology/benign prostatic hyperplasia (phosphodiesterase 5 inhibitor plus alpha-adrenoceptor antagonist).

Conclusion

Many research efforts have provided the basis for the development of new therapeutic modalities for the management of lower urinary tract dysfunctions, some of which might be offered to the patients in the near future.

Guess HA (1995) Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 22:247–261PubMed

Paolone DR (2010) Benign prostatic hyperplasia. Clin Geriatr Med 26:223–239PubMedCrossRef

Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA (2016) Benign prostatic hyperplasia. Nat Rev Dis Primers 2:16031PubMedCrossRef

Andersson KE (2002) Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 19:390–396PubMedCrossRef

Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha₁-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64:1081–1088PubMedCrossRef

Lepor H (2016) Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 43:311–323PubMedCrossRef

Roehrborn CG, Schwinn DA (2004) Alpha₁-adrenergic receptor and their inhibitors in lower urinary tract symptoms an benign prostatic hyperplasia. J Urol 171:1029–1035PubMedCrossRef

van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, Traudtner K, Drake MJ (for the NEPTUNE Study Group) (2013) Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 64:1003–1012CrossRef

Drake MJ, Oelke M, Snijder R, Klaver M, Traudtner K, van Charldorp K, Bongaerts D, van Kerrebroeck P (2017) Incidence of urinary retention during treatment with singe tablet combinations of solifenacin + tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: a subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One 12:e0170726PubMedPubMedCentralCrossRef

10.

Naslund MJ, Miner M (2007) A review of the clinical efficacy and safety of 5-alpha-reductase inhibitors for the enlarged prostate. Clin Ther 29:17–25PubMedCrossRef

11.

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS (2011) Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 108:388–394PubMedCrossRef

12.

Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, Palacios JM, Vasylyev A, Manyak MJ (2015) Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (DUODART) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int 16:450–459CrossRef

13.

de Nunzio C, Presicce F, Tubaro A (2016) Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia. Drugs Today (Barcelona) 52:501–517CrossRef

14.

Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA (2009) Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 74:431–435PubMedCrossRef

15.

Porst H, Kim ED, CasabE AR et al (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 60:1105–1113PubMedCrossRef

16.

Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L (2013) Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multi-national, randomized, placebo-controlled clinical studies. Urology 82:667–673PubMedCrossRef

17.

Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S (2013) Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 189(Suppl 1):S135–S140PubMed

18.

Dedhia RC, McVary KT (2008) Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 179:2119–2125PubMedCrossRef

19.

Sharma M, Chadha R, Dhingra N (2017) Phytotherapeutic agents for benign prostatic hyperplasia: an overview. Mini Rev Med Chem 17:1346–1363PubMed

20.

de Mey C (1998) Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol 34(Suppl 2):18–28 (Erratum in: Eur Urol (1998) 34:527) PubMedCrossRef

21.

Castiglione F, Benigni F, Briganti A, Salonia A, Villa L, Nini A, Di Trapani E, Capitanio U, Hedlund P, Montorsi F (2014) Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Curr Med Res Opin 30:719–732PubMedCrossRef

22.

Perumal C, Chowdhury PS, Ananthakrishnan N, Nayak P, Gurumurthy S (2015) A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urol Ann 7:74–78PubMedPubMedCentralCrossRef

23.

Tsuritani S, Nozaki T, Okumura A, Kimura H, Kazama T (2010) A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. Urol Int 85:80–87PubMedCrossRef

24.

Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T (2006) Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. Int J Urol 13:932–938PubMedCrossRef

25.

Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J (1994) Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 25:46–52PubMedCrossRef

26.

Tanaka T, Kuratsukuri K, Yoshimura R, Adachi T, Yamaguchi T, Ohmachi T, Yamamoto S, Nakamura T, Tamada S, Nakatani T (2015) Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing. Int J Urol 22:317–321PubMedCrossRef

27.

Chang RS, Chen TB, O’Malley SS, Pettibone DJ, DiSalvo J, Francis B, Bock MG, Freidinger R, Nagarathnam D, Miao SW, Shen Q, Lagu B, Murali Dhar TG, Tyagarajan S, Marzabadi MR, Wong WC, Gluchowski C, Forray C (2000) In vitro studies on L-771.688 (SNAP 6383), a new potent and selective alpha_1A-adrenoceptor antagonist. Eur J Pharmacol 409:301–312PubMedCrossRef

28.

Ford AP, Arredondo NF, Blue DR Jr, Bonhaus DW, Jasper J, Kava MS, Lesnick J, Pfister JR, Shieh IA, Vimont RL, Williams TJ, McNeal JE, Stamey TA, Clarke DE (1996) RS-17053 (N-[2-(2-cyclopropyl-methoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha_1A-adrenoceptor antagonist, displays low affinity for functional alpha₁-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol 49:209–215PubMed

29.

Marshall I, Burt RP, Green GM, Hussain MB, Chapple CR (1996) Different subtypes of alpha_1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS-17053. Br J Pharmacol 119:407–415PubMedPubMedCentralCrossRef

30.

Hedlund P, Ekstrom P, Larsson B, Alm P, Andersson KE (1997) Heme oxygenase and NO-synthase in the human prostate—relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 63:115–126PubMedCrossRef

31.

Hedlund P, Larsson B, Alm P, Andersson KE (1996) Nitric oxide synthase-containing nerves and ganglia in the dog prostate: a comparison with other transmitters. Histochem J 28:635–642PubMedCrossRef

32.

Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H (1995) Effects of nitric oxide on human and canine prostates. Urology 45:440–446PubMedCrossRef

33.

Naibar-Kaszkiel AT, Di Iulio JL, Li CG, Rand MJ (1997) Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs. Eur J Pharmacol 337:251–258CrossRef

34.

Hennenberg M, Schott M, Kan A, Keller P, Tamalunas A, Ciotkowska A, Rutz B, Wang Y, Strittmatter F, Herlemann A, Yu Q, Stief CG, Gratzke C (2016) Inhibition of adrenergic and non-adrenergic smooth muscle contraction in the human prostate by the phosphodiesterase 10-selective inhibitor TC-E 5005. Prostate 76:1364–1374PubMedCrossRef

35.

Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5:2170–2178PubMedCrossRef

36.

Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, Yang SK, Lee SW, Moon KH, Ahn TY, Kim SW, Park K, Min KS, Ryu JK, Son H, Jung J, Hyun JS (2017) Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafil for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial. J Sex Med 14:1018–1027PubMedCrossRef

37.

Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723PubMedCrossRef

38.

Fawzi A, Kamel M, Salem E, Desoky E, Omran M, Elgalaly H, Sakr A, Maarouf A, Khalil S (2016) Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: a randomised, double-blind, placebo-controlled trial. Arab J Urol 15:53–59PubMedPubMedCentralCrossRef

39.

Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M (2012) A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9:1624–1633PubMedCrossRef

40.

Mason RP, Cockcroft JR (2006) Targeting nitric oxide with drug therapy. J Clin Hypertens (Greenwich) 8(Suppl 4):40–52CrossRef

41.

Scatena R, Bottoni P, Martorana GE, Giardina B (2005) Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 14:835–846PubMedCrossRef

42.

Oliveira-Paula GH, Tanus-Santos JE (2019) Nitrite-stimulated gastric formation of S-nitrosothiols as an antihypertensive therapeutic strategy. Curr Drug Targets 20:431–443PubMedCrossRef

43.

Kedia GT, Ückert S, Kedia M, Truss MC, Chigogidze T, Jonas U, Managadze LG (2006) In vitro effects of cyclic AMP- and cyclic GMP-stimulating drugs on the relaxation of the prostate smooth muscle tissue contraction induced by endothelin-1. Georgian Med News 131:7–13

44.

Kedia GT, Ückert S, Scheller F, Chigogidze T, Managadze L, Jonas U, Truss MC (2006) In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 67:1292–1297PubMedCrossRef

45.

Heuer O, Ückert S, Dobler G, Klocker H, Stief CG, Truss MC, Bartsch G, Jonas U (2004) Effects of phosphodiesterase inhibitors and nitric oxide donors on cultured human prostatic smooth muscle cells. Eur Urol 3(Suppl 2):19 (Abstract, presented at the 19th Congress of the European Association of Urology (EAU), Vienna, Austria, 24-March to 27-March 2004) CrossRef

46.

Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer AE, Bartsch G, Frauscher F (2005) Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 96:1073–1078PubMedCrossRef

47.

Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T, Kinoshita Y, Tomita S (2014) Prostatic ischemia induces ventral prostatic hyperplasia in the SHR: possible mechanism of development of BPH. Sci Rep 4:3822PubMedPubMedCentralCrossRef

48.

Fernandes VS, Martínez-Sáenz A, Recio P, Ribeiro AS, Sánchez A, Martínez MP, Martínez AC, García-Sacristán A, Orensanz LM, Prieto D, Hernández M (2011) Mechanisms involved in nitric oxide-induced vasorelaxation in porcine prostatic arteries. Naunyn Schmiedebergs Arch Pharmacol 384:245–253PubMedCrossRef

49.

Roshani A, Khosropanah I, Salehi M, Kamran AN (2010) Effects of isosorbide dinitrate on the urinary flow rate in patients with benign prostatic hyperplasia. Urol J 7:183–187PubMed

50.

Tadayyon F, Izadpanahi M, Aali S, Mazdak H, Khorrami MH (2012) The effect of sublingual isosorbide dinitrate on acute urinary retention due to benign prostatic hyperplasia. Saudi J Kidney Dis Transpl 23:782–785PubMedCrossRef

51.

Klotz T, Mathers MJ, Bloch W, Nayal W, Engelmann U (1999) Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 31:335–341PubMedCrossRef

52.

Hedlund P (2005) Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract—is there a basis for pharmacological targeting of cGMP? World J Urol 23:362–367PubMedCrossRef

53.

Kedia GT, Ückert S, Jonas U, Kuczyk MA, Burchardt M (2008) The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 26:603–609PubMedCrossRef

54.

Siejka A, Schally AV, Block NL, Barabutis N (2010) Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int 106:1382–1388PubMedCrossRef

55.

Rozsa B, Nadji M, Schally AV, Dezso B, Flasko T, Toth G, Mile M, Block NL, Halmos G (2011) Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix. Prostate 71:445–452PubMedCrossRef

56.

Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L (2001) LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 71:736–747CrossRef

57.

Debruyne F, Tzvetkov M, Altarac S, Geavlete PA (2010) Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelixpamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 76:927–933PubMedCrossRef

58.

Swaminathan S (2011) Molecular structures and functional relationships in clostridial neurotoxins. FEBS J 278:4467–4485PubMedCrossRef

59.

Lam KH, Yao G, Jin R (2015) Diverse binding modes, same goal: the receptor recognition mechanism of botulinum neurotoxin. Prog Biophys Mol Biol 117:225–231PubMedPubMedCentralCrossRef

60.

Chartier-Kastler E, Mehnert U, Denys P, Giuliano F (2009) Perspective of Botox for treatment of male lower urinary tract symptoms. Curr Opin Urol 19:20–25CrossRef

61.

Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G (2009) Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 73:90–94PubMedCrossRef

62.

Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB (2006) Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98:1033–1037PubMedCrossRef

63.

Sacco E, Bientinesi R, Marangi F, Totaro A, D’Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P (2012) Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic onabotulinumtoxin A: 3 month results of a prospective single-armed cohort study. BJU Int 110(11):E837–E844PubMedCrossRef

64.

Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, Zhou J, Patel A, Haag-Molkenteller C (2013) A randomized double-blind, placebo-controlled phase 2 dose-ranging study of onabotulinumtoxin A in men with benign prostatic hyperplasia. Eur Urol 63:496–503PubMedCrossRef

65.

Shim SR, Cho YJ, Shin IS, Kim JH (2016) Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol 48:19–30PubMedCrossRef

66.

Comeglio P, Chavalmane AK, Fibbi B, Filippi S, Marchetta M, Marini M, Morelli A, Penna G, Vignozzi L, Vannelli GB, Adorini L, Maggi M (2010) Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. J Endocrinol Invest 33:730–738PubMedCrossRef

67.

Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, Crescioli C, Donati S, Fibbi B, Colli E, Adorini L, Maggi M (2007) BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 67:234–247PubMedCrossRef

68.

Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M, Colli E, Maggi M, Adorini L (2009) The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappa B pathways. Prostate 69:480–493PubMedCrossRef

69.

Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Fibbi B, Morelli A, Uskokovic M, Colli E, Maggi M (2007) Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 103:689–693PubMedCrossRef

70.

Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, Scarpa R, Usai P, Olivieri L, Maggi M (for the BPH Italian Study Group) (2006) BXL-628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 49:82–86CrossRef

71.

Hanley MR, Benton HP, Lightman SL, Todd K, Bone EA, Fretten P, Palmer S, Kirk CJ, Michell RH (1984) A vasopressin-like peptide in the mammalian sympathetic nervous system. Nature (London) 309:258–261CrossRef

72.

van Kerrebroeck P (2011) Nocturia: current status and future perspectives. Curr Opin Obstet Gynecol 23:376–385PubMed

73.

Oelke M, Adler E, Marschall-Kehrel D, Herrmann TR, Berges R (2014) Nocturia: state of the art and critical analysis of current assessment and treatment strategies. World J Urol 32:1109–1117PubMedCrossRef

74.

Ali F, Guglin M, Vaitkevicius P, Ghali JK (2007) Therapeutic potential of vasopressin receptor antagonists. Drugs 67:847–858PubMedCrossRef

75.

Lemmens-Gruber R, Kamyar M (2008) Pharmacology and clinical relevance of vasopressin antagonists. Der Internist (Berlin) 49:628–634CrossRef

76.

Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB, Tyagi P (2008) Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedeberg’s Arch Pharmacol 377(4–6):437–448CrossRef

77.

Bodanszky M, Sharaf H, Roy JB, Said SI (1992) Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. Eur J Pharmacol 216:311–313PubMedCrossRef

78.

Crankshaw D (1989) [Arg8]vasopressin-induced contractions of rabbit urinary bladder smooth muscle. Eur J Pharmacol 173(2–3):183–188PubMedCrossRef

79.

Gupta J, Russell R, Wayman C, Hurley D, Jackson V (2008) Oxytocin-induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V1A receptors and not oxytocin receptors. Br J Pharmacol 155:118–126PubMedPubMedCentralCrossRef

80.

Palea S, Corsi M, Artibani W, Ostardo E, Pietra C (1996) Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate. J Pharmacol Exp Ther 277:700–705PubMed

81.

Malherbe P, Ballard TM, Ratni H (2011) Tachykinin neurokinin 3 receptor antagonists: a patent review (2005–2010). Expert Opin Ther Pat 21:637–655PubMedCrossRef

82.

Bakali E, Elliott RA, Taylor AH, Willets J, Konje JC, Tincello DG (2013) Distribution and function of the endocannabinoid system in the rat and human bladder. Int Urogynecol J 24:855–863PubMedCrossRef

83.

Hedlund P (2014) Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol Urodyn 33:46–53PubMedCrossRef

84.

Hedlund P, Gratzke C (2016) The endocannabinoid system—a target for the treatment of LUTS? Nat Rev Urol 13:463–470PubMedCrossRef

85.

Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, Andersson KE, Hedlund P (2010) Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol 57:902–910PubMedCrossRef

86.

Shore N (2010) NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19:305–310PubMedCrossRef

87.

Shore N, Cowan B (2011) The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis 2:283–377CrossRef

88.

Kunit T, Lusuardi L (2014) An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia. Res Rep Urol 6:67–70PubMedPubMedCentral

89.

Shore N, Tutrone R, Efros M, Bidair M, Wachs B, Kalota S, Freedman S, Bailen J, Levin R, Richardson S, Kaminetsky J, Snyder J, Shepard B, Goldberg K, Hay A, Gange S, Grunberger I (2018) Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol 36:801–809PubMedPubMedCentralCrossRef

90.

Brawer MK (2005) Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol 7(Suppl 7):S21–S526PubMedPubMedCentral

91.

Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, Roman J, Zhou R, Leeper DB, Halestrap AP, Blair IA, Glickson JD (2016) Mechanism of anti-neoplastic activity of lonidamine. Biochim Biophys Acta 1866:151–162PubMedPubMedCentral

92.

Roehrborn CG (2005) The development of lonidamine for benign prostatic hyperplasia and other indications. Rev Urol 7(Suppl 7):S12–S620PubMedPubMedCentral

93.

Ditonno P, Battaglia M, Selvaggio O, Garofalo L, Lorusso V, Selvaggi FP (2005) Clinical evidence supporting the role of lonidamine for the treatment of BPH. Rev Urol 7(Suppl 7):S27–S533PubMedPubMedCentral

Titel: Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate
verfasst von: Stefan Ückert
George T. Kedia
Dimitrios Tsikas
Annika Simon
Andreas Bannowsky
Markus A. Kuczyk
Publikationsdatum: 10.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02933-1

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Biopsy Grade Group as a reliable prognostic factor for BCR in Afro-Caribbean men with intermediate- and high-risk prostate cancer

Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients

En bloc greenlight laser enucleation of prostate (GreenLEP): about the first hundred cases

Surgical safety in radical cystectomy: the anesthetist's point of view—how to make a safe procedure safer